Mohammad Al Shroof, MD
Internal Medicine · Warner Robins, GANPI 1578519286
Payments from drug & device makers
Across 1,359 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- AstraZeneca$2K
- Amgen$1K
- Pfizer$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $13K from 54 others
What the payments were for
- Food & beverage$22,378100%
- Education$1090%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$357
- Korlym$222
- INVOKANA$146
- Veozah$125
- JARDIANCE$124
- TRELEGY ELLIPTA$124
- Leqembi$122
- iLet Insulin Infusion Kit Inset$119
- iLet Insulin Infusion Kit Contact Detach$119
- Repatha$107
How this compares
$22,487 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 292 | $397,870 |
| EliquisApixaban | 575 | $332,895 |
| MounjaroTirzepatide | 225 | $312,517 |
| JardianceEmpagliflozin | 235 | $197,587 |
| FarxigaDapagliflozin Propanediol | 146 | $138,209 |
| LinzessLinaclotide | 165 | $132,553 |
| JanuviaSitagliptin Phosphate | 133 | $107,655 |
| XareltoRivaroxaban | 121 | $102,067 |
| Enbrel SureclickEtanercept | 12 | $92,402 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $90,941 |
| Tresiba Flextouch U-200Insulin Degludec | 77 | $68,833 |
| Tresiba Flextouch U-100Insulin Degludec | 112 | $67,935 |
| RybelsusSemaglutide | 36 | $64,328 |
| EntrestoSacubitril/Valsartan | 59 | $63,202 |
| RexultiBrexpiprazole | 30 | $57,480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,983 | $462,198328 claims |
| Lilly USA, LLCMounjaro, Trulicity | $956 | $333,872239 claims |
| PfizerEliquis | $1,267 | $332,895575 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $440 | $250,226353 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $1,599 | $211,254255 claims |
| AbbVieLinzess, Vraylar | $1,868 | $171,803196 claims |
| MerckJanuvia, Janumet Xr | $402 | $143,532171 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $986 | $115,033155 claims |
| Johnson & JohnsonXarelto | $911 | $102,067121 claims |
| NovartisEntresto | $388 | $63,20259 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,191 | $57,48030 claims |
| Astellas Pharma US IncMyrbetriq | $1,133 | $51,50675 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Warner Robins
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.